Form 4: Inhibrx Biosciences Director Transfers Shares to Family Trusts

Director Jon Faiz Kayyem transferred 500,000 shares of Inhibrx Biosciences stock to family trusts on December 16, 2024.

Summary

• Jon Faiz Kayyem, a director at Inhibrx Biosciences, transferred 500,000 shares of common stock from The Jon F. Kayyem and Paige Gates-Kayyem Family Trust.
• The shares were transferred to two new trusts: the Jon Faiz Kayyem Revocable Trust (250,000 shares) and the Paige Gates-Kayyem Revocable Trust (250,000 shares).
• The transfer was made for no consideration, meaning no money was exchanged.
• Following the transaction, Mr. Kayyem indirectly owns 509,360 shares through The Jon F. Kayyem and Paige Gates-Kayyem Family Trust.
• Additionally, Mr. Kayyem's children indirectly own 69,843 shares each through custodial accounts.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock transfer, with no positive or negative implications for the company's performance.

Industry Context

This is a routine filing related to changes in beneficial ownership by a company director and is not indicative of any broader industry trend.

Comparison to Industry Standards

• Form 4 filings are standard practice for company insiders and directors when they make transactions involving company stock.
• The transfer of shares to family trusts is a common estate planning strategy and does not indicate any unusual activity compared to other companies.

Stakeholder Impact

• The transaction has no immediate impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Keywords

Inhibrx Biosciences, Jon Faiz Kayyem, stock transfer, beneficial ownership, family trust, director, INBX